Matches in SemOpenAlex for { <https://semopenalex.org/work/W2077237194> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W2077237194 endingPage "163" @default.
- W2077237194 startingPage "159" @default.
- W2077237194 abstract "On the basis of in vitro studies demonstrating marked synergy between mitoxantrone and high-dose cytosine arabinoside (ara-C) (HiDAC) against L5178Y murine leukemia and clinical studies showing usefulness of the combination in patients with refractory acute myeloid leukemia, a phase I study was initiated to find tolerable doses for use in patients with refractory solid tumors. Initial dose levels were mitoxantrone 2 mg/m2 infused over 30 minutes, followed by high-dose ara-C 750 mg/m2 infused over 3 hours repeated once at 24 hours (total dose 4 mg/m2 mitoxantrone and 1,500 mg/m2 Hi-DAC per 2-day course), with planned subsequent escalation of mitoxantrone. Moderate-to-severe myelosuppression, however, required sequential dose reduction of both agents. Nonhematologic toxicity was restricted to manageable nausea and vomiting in one-half the patients and a single episode of transient delirium of uncertain etiology. No responses were observed in 23 heavily pretreated patients with a wide variety of malignancies. On the basis of this study, doses of 187–375 mg/m2 ara-C given every 24 hours for two doses following mitoxantrone 1 mg/m2 every 24 hours for two doses would be tolerated by most patients with subsequent dose escalation in some as allowed by myelosuppression." @default.
- W2077237194 created "2016-06-24" @default.
- W2077237194 creator A5007726590 @default.
- W2077237194 creator A5030342776 @default.
- W2077237194 creator A5044402819 @default.
- W2077237194 creator A5050522029 @default.
- W2077237194 creator A5055271621 @default.
- W2077237194 creator A5060562909 @default.
- W2077237194 creator A5077617331 @default.
- W2077237194 creator A5089163859 @default.
- W2077237194 date "1989-01-01" @default.
- W2077237194 modified "2023-09-28" @default.
- W2077237194 title "Mitoxantrone and high-dose ara-C in refractory malignancies: A phase I trial" @default.
- W2077237194 cites W1591796471 @default.
- W2077237194 cites W1965377737 @default.
- W2077237194 cites W2017366147 @default.
- W2077237194 cites W2035141991 @default.
- W2077237194 cites W2035159229 @default.
- W2077237194 cites W2038338634 @default.
- W2077237194 cites W2042016893 @default.
- W2077237194 cites W2047435984 @default.
- W2077237194 cites W2068121922 @default.
- W2077237194 cites W2068743999 @default.
- W2077237194 cites W2096830830 @default.
- W2077237194 cites W2127264662 @default.
- W2077237194 cites W2167805334 @default.
- W2077237194 doi "https://doi.org/10.1002/mpo.2950170217" @default.
- W2077237194 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2704336" @default.
- W2077237194 hasPublicationYear "1989" @default.
- W2077237194 type Work @default.
- W2077237194 sameAs 2077237194 @default.
- W2077237194 citedByCount "1" @default.
- W2077237194 crossrefType "journal-article" @default.
- W2077237194 hasAuthorship W2077237194A5007726590 @default.
- W2077237194 hasAuthorship W2077237194A5030342776 @default.
- W2077237194 hasAuthorship W2077237194A5044402819 @default.
- W2077237194 hasAuthorship W2077237194A5050522029 @default.
- W2077237194 hasAuthorship W2077237194A5055271621 @default.
- W2077237194 hasAuthorship W2077237194A5060562909 @default.
- W2077237194 hasAuthorship W2077237194A5077617331 @default.
- W2077237194 hasAuthorship W2077237194A5089163859 @default.
- W2077237194 hasConcept C121332964 @default.
- W2077237194 hasConcept C126322002 @default.
- W2077237194 hasConcept C142424586 @default.
- W2077237194 hasConcept C2776694085 @default.
- W2077237194 hasConcept C2778041864 @default.
- W2077237194 hasConcept C2778461978 @default.
- W2077237194 hasConcept C2780580376 @default.
- W2077237194 hasConcept C2780852908 @default.
- W2077237194 hasConcept C2780923524 @default.
- W2077237194 hasConcept C29730261 @default.
- W2077237194 hasConcept C42219234 @default.
- W2077237194 hasConcept C71924100 @default.
- W2077237194 hasConcept C87355193 @default.
- W2077237194 hasConcept C90924648 @default.
- W2077237194 hasConcept C98274493 @default.
- W2077237194 hasConceptScore W2077237194C121332964 @default.
- W2077237194 hasConceptScore W2077237194C126322002 @default.
- W2077237194 hasConceptScore W2077237194C142424586 @default.
- W2077237194 hasConceptScore W2077237194C2776694085 @default.
- W2077237194 hasConceptScore W2077237194C2778041864 @default.
- W2077237194 hasConceptScore W2077237194C2778461978 @default.
- W2077237194 hasConceptScore W2077237194C2780580376 @default.
- W2077237194 hasConceptScore W2077237194C2780852908 @default.
- W2077237194 hasConceptScore W2077237194C2780923524 @default.
- W2077237194 hasConceptScore W2077237194C29730261 @default.
- W2077237194 hasConceptScore W2077237194C42219234 @default.
- W2077237194 hasConceptScore W2077237194C71924100 @default.
- W2077237194 hasConceptScore W2077237194C87355193 @default.
- W2077237194 hasConceptScore W2077237194C90924648 @default.
- W2077237194 hasConceptScore W2077237194C98274493 @default.
- W2077237194 hasIssue "2" @default.
- W2077237194 hasLocation W20772371941 @default.
- W2077237194 hasLocation W20772371942 @default.
- W2077237194 hasOpenAccess W2077237194 @default.
- W2077237194 hasPrimaryLocation W20772371941 @default.
- W2077237194 hasRelatedWork W2006876985 @default.
- W2077237194 hasRelatedWork W2062064479 @default.
- W2077237194 hasRelatedWork W2074629895 @default.
- W2077237194 hasRelatedWork W2076411732 @default.
- W2077237194 hasRelatedWork W2349679547 @default.
- W2077237194 hasRelatedWork W2358739720 @default.
- W2077237194 hasRelatedWork W2362862715 @default.
- W2077237194 hasRelatedWork W2399260822 @default.
- W2077237194 hasRelatedWork W2415576058 @default.
- W2077237194 hasRelatedWork W2897258609 @default.
- W2077237194 hasVolume "17" @default.
- W2077237194 isParatext "false" @default.
- W2077237194 isRetracted "false" @default.
- W2077237194 magId "2077237194" @default.
- W2077237194 workType "article" @default.